Skip to main content
. 2018 Apr 11;16:95. doi: 10.1186/s12967-018-1475-x

Table 3.

Comparative analysis of the clinicopathological factors according to the expression of GLUT-1

Variables GLUT-1
Low
n = 24 (48.0%)
GLUT-1
High
n = 26 (52.0%)
Univariable P*
Clinical factors
 Sex
  Male/female 13/11 16/10 0.775
 Age (years) 68 (32 − 83) 70 (46 − 81) 0.303
 CEA (ng/mL) 2.8 (0.4 − 8.8) 3.6 (0.7 − 133.1) 0.265
 CA19-9 (IU/mL) 38.7 (0.7 − 766) 65.5 (0.8 − 3055) 0.593
 SUVmax 4.5 (2.9 − 9.2) 7.0 (3.6 − 14.7) < 0.001
 MTV (cm3) 8.4 (1.5 − 604.0) 72.0 (3.6 − 777.0) 0.008
 TLG (g) 20.2 (3.6 − 3201.2) 259.2 (27.0 − 3418.8) < 0.001
 Tumor size (cm)
  Radiographical 3.5 (1.0 − 11.0) 4.0 (1.0 − 14.0) 0.108
Treatment factors
 R0 resection, n (%) 23 (95.8) 25 (96.2) 1.000
 Minor hepatectomy, n (%) 4 (16.7) 2 (7.7) 0.409
 Morbidity
  C-D class III/IV, n (%) 5 (20.8) 7 (26.9) 0.745
 Preoperative chemotherapy
  Present, n (%) 0 0 0
 Adjuvant chemotherapy
  Present, n (%) 17 (70.8) 13 (50.0) 0.159
Pathological factors
 Tumor differentiation
  Well/moderate, n (%) 22 (91.7) 21 (80.8) 0.420
  Poor, n (%) 2 (8.3) 5 (19.2)
 Vascular invasion
  Present, n (%) 18 (75.0) 16 (61.5) 0.372
 Bile duct invasion
  Present, n (%) 11 (45.8) 13 (50.0) 0.785
 Lymph node metastasis
  Present, n (%) 7 (29.2) 8 (30.8) 1.000
 Tumor number
  Multiple, n (%) 2 (8.3) 13 (50.0) 0.002
 Tumor size (cm) (pathological) 3.2 (1.0 − 10.8) 4.0 (1.2 − 14.0) 0.073
 AJCC stage
  IV, n (%) 8 (33.3) 17 (65.4) 0.047

AJCC American joint committee on cancer/international union against cancer classification, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, MTV metabolic tumor volume, SUVmax maximum standardized uptake value, GLUT-1 glucose transporter-1, R0 resection no macroscopic and microscopic tumor remaining, C-D, Clavien-Dindo classification system

*Statistically significant differences (P < 0.05) are shown in italic